NCT Number: NCT04528797
Thyroid and Adrenocortical Hormone Replacement in Organ Donors
Brain death inevitably leads to hemodynamic instability and prolonged hypotension that compromises viability of potentially transplantable organs. In addition to depletion of peripheral norepinephrine stores, concomitant depletion of thyroid hormone and cortisol levels are believed to contribute to this instability. Catecholamine vasopressors are widely used to support hemodynamics in potential organ donors, however their use has also been shown to compromise allograft function.
Trials studying the effects of thyroid hormone and corticosteroid treatment on brain dead organ donors have had mixed results with respect to improving donor hemodynamics. Further, few studies have attempted to discriminate the relative contribution of thyroid hormone vs. corticosteroids.
The specific aims of this study include:
1. To quantify hemodynamic changes during the management of cadaveric organ donors routinely receiving thyroid hormone therapy alone vs. corticosteroid therapy alone vs. the combination, compared to those who do not receive any hormonal therapy (controls) 2. To document number and types of organs procured in donors treated with thyroid hormone therapy alone vs. corticosteroid therapy alone vs. the combination, compared to those not treated with hormonal therapy (controls) 3. To quantify graft and patient outcomes in recipients of organs exposed to thyroid hormone therapy alone vs. corticosteroid therapy alone vs. the combination, compared to recipients of organs not exposed to hormonal therapy (controls).
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Not applicable
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Cadaveric organ donors ≥ age 18 having valid consent (by advance directive or by familial consent) to donate organs.
Recipients of these cadaveric organs
Exclusion criteria
Cadavers failing to meet inclusion criteria
Treatment and study plan
methylprednisolone
DrugPrimary outcomes
-
Change in Vasoactive Inotrope Score (VIS) score from beginning of active donor management until procurement.
Time frame: From baseline (t0) = beginning of active donor management to procurement (tOR) = time of organ procurement, up to 50 hours
The VIS score includes all commonly used vasopressor and inotrope agents, weighted by potency and summed
Secondary outcomes
-
Proportion of organs procured vs. consented, stratified by treatment group
Time frame: assessed at time of procurement, up to 50 hours following consent for donation
-
Recipient Morbidity
Time frame: 90 days post transplant
Selected graft recipient morbidity measures in all organs transplanted stratified by treatment group
-
Recipient Mortality
Time frame: 90 days post traansplant
Recipient death by 90 days post transplant
Sponsors and collaborators
Lead sponsor
Medical University of South Carolina
Other
Collaborators
- We Are Sharing Hope SC
Registry information
Official study title
Cadaveric Organ Donor Management: Thyroid and Adrenocortical Hormone Replacement
Important dates
- Study start
- 2010
- Primary completion
- 2012
- Study completion
- 2013
- First posted
- Aug 27, 2020
- Registry last updated
- Aug 27, 2020
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Cyclosporine A Pretreatment and Kidney Graft Function
NCT02907554
Brain Death, Brain Diseases
Clermont-Ferrand, France
View Trial DetailsThe Anticipated Organ Donation Approach
NCT03765814
Brain Death, Brain Diseases
Pringy, Haute Savoie, France
View Trial DetailsDetermining ICU Staffs Conceptions, Opinions, Views, Experiences and Reflection of Brain Death and Organ Donation
NCT06640088
Brain Death, Brain Diseases
Basel, Switzerland
View Trial DetailsORI and ETCO₂ Relationship With Arterial Blood Gas During Apnea Test
NCT06983990
Brain Death, Brain Diseases
Bursa, Turkey (Türkiye)
View Trial Details